Sponsors
The bill tightens legal definitions, data reporting, and coordinated enforcement to reduce counterfeit fentanyl/meth pill harms and improve prevention, but does so at the risk of increased criminalization, higher costs, potential exposure of sensitive investigations, and rushed policymaking that may undermine community trust and effectiveness.
Law enforcement and prosecutors will have clearer statutory authority to treat fentanyl- or methamphetamine-containing products packaged to look like legitimate items as 'counterfeit,' improving the ability to pursue sellers and reduce the supply of deadly fake pills.
Young people and the general public will get improved, data-driven prevention and education (including youth-targeted efforts and audited public-awareness campaigns), which should reduce accidental overdoses from counterfeit pills.
Federal agencies will provide annual aggregated data on counterfeit fentanyl/meth pills, increasing transparency and giving local jurisdictions better information to tailor prevention and response efforts.
People who use drugs — and some young or low-income communities — could face increased criminalization and prosecutions because broader definitions and stronger enforcement lower barriers to charging.
Manufacturers, distributors, and other businesses may face expanded liability, ambiguous litigation risk, and higher compliance costs if packaging similarities are disputed or the prohibited conduct is interpreted broadly.
Strengthening enforcement, running expanded public-awareness campaigns, and producing comprehensive annual reports will impose additional costs on DOJ/DEA/ONDCP and taxpayers and could divert agency resources from frontline work.
Based on analysis of 5 sections of legislative text.
Defines counterfeit fentanyl/methamphetamine pills, adjusts a federal criminal provision's scope, requires a DEA response plan (180 days) and annual DOJ/DEA/ONDCP reports on seizures, testing, and prosecutions.
Introduced March 19, 2026 by Gabe Evans · Last progress March 19, 2026
Creates a federal definition of “counterfeit fentanyl or methamphetamine substance,” changes the scope of an existing federal criminal prohibition related to those substances, requires the DEA to produce an operational response plan within 180 days, and requires the Attorney General (with DEA and ONDCP) to send Congress annual reports on seizures, testing, prosecutions, and prevention efforts. The DEA plan must strengthen investigations and seizures, expand education and prevention (with attention to youth), and audit public-awareness campaigns; the annual report must include aggregate seizure counts, pill-form breakdowns, spatiotemporal data, charging/conviction information, and descriptions of prevention and outreach activity.